[Contagious impetigo--pathogen spectrum and therapeutic consequences].
OBJECTIVE
The aim of this prospective study was to compare the clinical picture of contagious impetigo (C.I.) with the causative organism and to generate data of the susceptibility of bacteria as the basis for adequate therapy.


METHODS
In 126 patients with C.I. (86 children, 66 of them younger than 10 years) bacterial swabs were taken and antibiotic sensitivity testing for isolated organisms was tested.


RESULTS
In all cases in which contents of vesicles or pustules were analysed, Staphylococcus aureus was the only pathogen isolated. In non-bullous variants of C.I. Staphylococcus aureus was the most often isolated organism as well. Both staphylococci and streptococci were isolated in 12 cases, whereas in just 9 cases streptococci were the only pathogen detected. All Staphylococcus aureus isolates were sensitive to flucloxacillin and cefotaxime. Erythromycin-resistance amounted to more than 20 percent. The percentage of resistant staphylococci against the predominantly topically applied antibiotics fusidinic acid and mupirocin was 2 and 0 per cent, respectively.


CONCLUSIONS
For all manifestations of C.I. Staphylococcus aureus is at present the leading organism which has to be taken into consideration for treatment. If oral antibiotic therapy is indicated, penicillinase-stable penicillins or cephalosporins, preferably of the cefalexin-type, are the drugs of choice. Macrolides are no longer recommended for initiating of C.I. treatment.
Abeck
D
D
Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Technischen Universität München. D.Abeck@lrz.tu-muenchen.de
Mempel
M
M
Seidl
H P
HP
Schnopp
C
C
Ring
J
J
Heeg
K
K
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003354:Corynebacterium Infections / Q000175:diagnosis* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007169:Impetigo / Q000175:diagnosis* / Q000188:drug therapy; D007223:Infant; D008297:Male; D008826:Microbial Sensitivity Tests; D011446:Prospective Studies; D013203:Staphylococcal Infections / Q000175:diagnosis* / Q000188:drug therapy; D013290:Streptococcal Infections / Q000175:diagnosis* / Q000188:drug therapy
D000900:Anti-Bacterial Agents